Men's Health
Basic InformationLatest News
AHA News: Hormone Therapy No Cure-All For 'Low T' In Aging MenAHA News: Instead of a Tie, Think About Healthy Gifts and Gratitude for Father's DayProstate Cancer Drug Could Be 'Game Changing,' Researchers SayWith PSA Test Out of Favor, Cases of Advanced Prostate Cancer Are RisingCOVID-19 Continues to Strike Men Harder Than WomenExercise Helps Men During Hormone Treatment for Prostate Cancer: StudyProstate Cancer Leaves Detectable 'Fingerprint' in Blood: StudyCould Dad-to-Be's Health Affect His Newborn's Health?Lose Weight, Lower Prostate Cancer RiskCholesterol Drugs Might Help Curb 'High-Risk' Prostate Cancers'Tough Guys' May Be at Especially High Risk for SuicideCould ED Drugs Threaten Men's Vision?With Equal Access to Care, Blacks, Whites Have Similar Prostate Cancer OutcomesAt the Barbershop, a Trim -- and a Diabetes ScreeningEating More Veggies Won't Stop Prostate Cancer: StudyFish Oil Supplements Might Help Men Become DadsAI Might Help Spot, Evaluate Prostate CancerWhat Works Best to Help Men With Overactive Bladder?'Less Is More' When it Comes to Testicular Cancer Chemo, Study SuggestsMale Fertility Supplements Fail to DeliverTestosterone Supplements Won't Help Most Men, Doctors' Group SaysCould Baldness Become 'Optional'? New Research May Give Men HopeAHA News: Erectile Dysfunction May Up the Odds for Irregular HeartbeatMuscle in Middle Age Might Help Men's Hearts LaterTestosterone Supplements Double Men's Odds for Blood Clots: StudyBeyonce's Dad Puts Spotlight on Male Breast CancerFrequent Male Pot Use Linked to Early MiscarriagesUsing Opioids After Vasectomy May Trigger Persistent Use: StudyGene-Based Therapy Helps Fight Advanced Prostate CancerHigh-Dose Radiation a Game Changer in Fighting Deadly Prostate CancerAt-Risk Men May Also Benefit From Regular MammogramsDoubt Over Long-Term Use of Hormone Rx for Recurrent Prostate CancerWhat Is Your Risk for Prostate Cancer?For Men, Living Alone May Mean Poorer Control of Blood-Thinning MedsHormone Therapy for Prostate Cancer Might Harm the Heart: StudyAHA News: Common Prostate Cancer Treatment May Increase Risk of Fatal Heart ConditionHealth Cautions for Young Male AthletesOverweight Men May Feel Stigmatized, TooTestosterone Therapy May Threaten the HeartTestosterone Doesn't Spur Atherosclerosis in Older Men
Related Topics

Wellness and Personal Development
Mental Disorders

Gene-Based Therapy Helps Fight Advanced Prostate Cancer

HealthDay News
by By Amy Norton
HealthDay Reporter
Updated: Sep 30th 2019

new article illustration

MONDAY, Sept. 30, 2019 (HealthDay News) -- A drug that targets faulty gene repair may buy more time for some men with advanced prostate cancer, a new clinical trial finds.

Experts called the study "landmark," because it zeroed in on men with particular gene mutations that can be targeted with newer drug therapies. It's an approach that is already used in treating breast, ovarian and lung cancers.

Specifically, the trial tested a drug called Lynparza (olaparib), which is currently approved to treat certain patients with breast or ovarian cancers linked to mutations in the BRCA genes.

When BRCA is working properly, it helps repair damaged DNA in body cells that can lead to cancer; when the gene is altered, those repair mechanisms go awry.

BRCA mutations do not only lead to breast and ovarian cancers, though: They also help drive some cases of prostate cancer. In the new trial, researchers recruited men with advanced prostate cancer who had alterations in BRCA or certain other genes involved in DNA repair.

The investigators found that compared with standard hormonal therapy, Lynparza delayed patients' cancer progression for a median of about three months. That means half the patients saw a longer delay, and half a shorter one.

Along with that delay, the drug slowed down patients' pain progression.

"Delaying the cancer from growing is meaningful," said Dr. Maha Hussain, who led the trial, which was funded by drug makers Astra Zeneca and Merck.

"At the end of the day, patients want to live longer, and also better," added Hussain, a professor at Northwestern University Feinberg School of Medicine, in Chicago.

She was to present the findings Monday at the annual meeting of the European Society for Medical Oncology, in Barcelona. Studies reported at meetings are generally considered preliminary until they are published in a peer-reviewed journal.

Lynparza is one of a newer class of drugs called PARP inhibitors, which block a protein that cancer cells need to keep their DNA healthy. Without it, those cells may die; cancer cells with defects in DNA-repair genes are especially vulnerable to PARP inhibitors.

The drug class is part of a wider trend in cancer treatment, toward "targeted therapies" -- where medications are tailored to target certain molecules in cancer cells that help them grow and spread. A range of targeted drugs are available for common cancers, such as breast and lung, but prostate cancer has "lagged behind," Hussain said.

Dr. Eleni Efstathiou, of MD Anderson Cancer Center in Houston, described the new trial as landmark.

"Overall, these data show that, like breast and lung cancers, prostate cancer is not one but many different diseases," Efstathiou said. "We need to start identifying different groups of patients and treating them with targeted therapy."

She noted that only a fairly small percentage of prostate cancer patients would have alterations in DNA-repair genes -- which can be inherited or arise as the cancer progresses.

And doctors do not routinely screen cancers for all those gene flaws. Screening for inherited mutations is "becoming part of guidelines," Efstathiou noted, but screening for non-inherited alternations is not yet done.

For the latest trial, the researchers screened 4,425 men with advanced prostate cancer that had spread to distant sites in the body and was not responding to standard hormonal therapy. The investigators ended up with 245 patients with alterations in either BRCA or another gene called ATM; a second group of 142 patients had alterations in any of 12 other genes tied to flawed DNA repair.

Patients in both groups were randomly assigned to either take Lynparza tablets or start one of two newer hormonal therapies. Overall, Lynparza patients saw their cancer advance more slowly, with the difference being clearer in the group with BRCA or ATM defects.

For those men, cancer progression was delayed by a median of 7.4 months, versus 3.5 months among patients on hormonal therapy. A preliminary analysis suggested their overall survival was also better -- a median of 18.5 months, versus 15 months.

Lynparza does have side effects, including anemia and nausea, Efstathiou pointed out, which can make it difficult to stick with the drug. Just over 16% of Lynparza patients in the trial stopped treatment due to side effects.

The drug is not yet approved for prostate cancer, though some doctors use it "off-label" for certain patients, Hussain noted.

At this point, Efstathiou said, doctors may want to screen for DNA-repair mutations in the tumors of men with advanced prostate cancer, since "we now have evidence it can be successfully targeted."

Like other targeted drugs, Lynparza carries a hefty price tag: Researchers have estimated that it costs more than $234,000 to extend a patient's life by one year.

More information

The U.S. National Cancer Institute has more on targeted therapies for cancer.

328 W. Claiborne St.
P.O. Box 964
Alabama 36460
Tel: (251)575-4203

powered by centersite dot net